Debt-to-equity of 0.30 on $53.8 million of total debt looks moderate but has risen from 0.63 in 2026Q1 and was 0.29 in 2024Q2, while $140.6 million of goodwill against $41.1 million of cash highlights a thin liquidity cushion and impairment exposure.
Sana Biotechnology, Inc. (SANA) balance sheet — 8-year assets, liabilities & shareholders' equity history
| Metric | TTM | Dec'25 | Dec'24 | Dec'23 | Dec'22 | Dec'21 | Dec'20 | Dec'19 | Dec'18 |
|---|
| Total Current Assets | 132.31M | 148.68M | 160.81M | 213.51M | 444.44M | 558.1M | 384.47M | 144.26M | 32.6M |
| Cash & Short-Term Investments | 121.73M | 138.38M | 152.5M | 205.19M | 423.96M | 551M | 378.26M | 138.98M | 30.63M |
| Cash Only | 41.1M | 71.87M | 127.57M | 133.52M | 176.76M | 253.03M | 124.81M | 80.03M | 30.63M |
| Short-Term Investments | 80.62M | 66.51M | 24.93M | 71.68M | 247.2M | 297.97M | 253.46M | 58.95M | 0 |
| Accounts Receivable | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Days Sales Outstanding | - | - | - | - | - | - | - | - | - |
| Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Days Inventory Outstanding | - | - | - | - | - | - | - | - | - |
| Other Current Assets | 3.76M | 10.29M | 8.31M | 8.32M | 20.47M | 0 | 0 | 0 | 0 |
| Total Non-Current Assets | 243.81M | 268.21M | 340.21M | 351.78M | 378.28M | 571.31M | 345.83M | 270.93M | 1.74M |
| Property, Plant & Equipment | 43.44M | 65.22M | 135.27M | 145.59M | 159.4M | 161.78M | 109.94M | 68.81M | 585K |
| Fixed Asset Turnover | 0.00x | - | - | - | - | - | - | - | - |
| Goodwill | 140.63M | 140.63M | 140.63M | 140.63M | 140.63M | 140.63M | 140.63M | 140.63M | 0 |
| Intangible Assets | 59.2M | 59.2M | 59.2M | 59.2M | 59.2M | 59.2M | 59.2M | 59.2M | 0 |
| Long-Term Investments | 0 | 0 | 0 | 0 | 10.05M | 195.88M | 33.73M | 0 | 816K |
| Other Non-Current Assets | 551K | 3.17M | 5.12M | 6.37M | 9.01M | 13.82M | 2.33M | 2.3M | 336K |
| Total Assets | 376.13M | 416.89M | 501.02M | 565.3M | 822.72M | 1.13B | 730.3M | 415.19M | 34.33M |
| Asset Turnover | 0.00x | - | - | - | - | - | - | - | - |
| Asset Growth % | -27.22% | -16.79% | -11.37% | -31.29% | -27.15% | 54.65% | 75.89% | 1109.31% | - |
| Total Current Liabilities | 74.88M | 78.73M | 45.43M | 64.49M | 111.5M | 99.23M | 31.45M | 19.32M | 1.78M |
| Accounts Payable | 1.95M | 1.67M | 5.21M | 4.11M | 2.86M | 2.22M | 2.25M | 0 | 289K |
| Days Payables Outstanding | 270.96 | 47.78 | - | - | - | - | 80.85 | - | 105.48K |
| Short-Term Debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue (Current) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Current Liabilities | 40.65M | 51.93M | 300K | 23.46M | 76.59M | 74.63M | 14.02M | 8.09M | 685K |
| Current Ratio | 1.77x | 1.89x | 3.54x | 3.31x | 3.99x | 5.62x | 12.22x | 7.47x | 18.26x |
| Quick Ratio | 1.77x | 1.89x | 3.54x | 3.31x | 3.99x | 5.62x | 12.22x | 7.47x | 18.26x |
| Cash Conversion Cycle | - | - | - | - | - | - | - | - | - |
| Total Non-Current Liabilities | 120.88M | 177.28M | 205.08M | 213.31M | 211.9M | 301.67M | 1.12B | 538.41M | 45.74M |
| Long-Term Debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Capital Lease Obligations | 163.68M | 63.92M | 81.66M | 90.9M | 95.86M | 101.78M | 68.2M | 46.36M | 0 |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Liabilities | 80.36M | 113.36M | 123.42M | 122.41M | 116.04M | 199.89M | 1.05B | 492.05M | 45.74M |
| Total Liabilities | 195.76M | 256.01M | 250.52M | 277.79M | 323.4M | 400.9M | 1.15B | 557.73M | 47.52M |
| Total Debt | 53.84M | 78.86M | 94.2M | 104.1M | 108.25M | 110.94M | 71.91M | 47.7M | 0 |
| Net Debt | 12.74M | 6.99M | -33.37M | -29.42M | -68.51M | -142.09M | -52.9M | -32.33M | -30.63M |
| Debt / Equity | 0.30x | 0.49x | 0.38x | 0.36x | 0.22x | 0.15x | - | - | - |
| Debt / EBITDA | -0.41x | - | - | - | - | - | - | - | - |
| Net Debt / EBITDA | -0.10x | - | - | - | - | - | - | - | - |
| Interest Coverage | - | - | - | - | - | - | - | - | - |
| Total Equity | 180.36M | 160.88M | 250.5M | 287.51M | 499.31M | 728.5M | -421.18M | -142.54M | -13.19M |
| Equity Growth % | -60.28% | -35.78% | -12.87% | -42.42% | -31.46% | 272.97% | -195.48% | -980.85% | - |
| Book Value per Share | 0.58 | 0.64 | 1.08 | 1.48 | 2.65 | 4.38 | -2.25 | -0.76 | -0.07 |
| Total Shareholders' Equity | 180.36M | 160.88M | 250.5M | 287.51M | 499.31M | 728.5M | -421.18M | -142.54M | -13.19M |
| Common Stock | 30K | 27K | 22K | 20K | 19K | 18K | 2K | 1K | 1K |
| Retained Earnings | -1.94B | -1.85B | -1.6B | -1.34B | -1.05B | -785.36M | -429.43M | -144.13M | -13.25M |
| Treasury Stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Accumulated OCI | -104K | 28K | 14K | -60K | -4.33M | -1.37M | 30K | 26K | -45.72M |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Quick answers to the most common questions about buying SANA stock.
As of 2025, Sana Biotechnology, Inc. (SANA) had total assets of $416.9M including $148.7M in current assets.
Sana Biotechnology, Inc. (SANA) carries total debt of $78.9M, offset by $138.4M in cash and short-term investments. Comparing total debt to cash helps evaluate the company's debt burden and net leverage.
Sana Biotechnology, Inc. (SANA) has total shareholders' equity (book value) of $160.9M ($0.64 book value per share). Book value represents the net worth of the company belonging to common stock holders.
Sana Biotechnology, Inc. (SANA) reported a current ratio of 1.89x. A current ratio above 1.0x indicates that the company has more current assets than current liabilities, suggesting sufficient short-term liquidity.
Key Metrics
Top Statement Risk
Cash runway constraint and dilution
Metrics are mathematically derived from official filings.
Balance Sheet Shrinking Toward Liquidity Floor
Based on Sana's reported figures, total assets fell from $618.7 million in 2024Q2 to $376.1 million in 2026Q3, a decline of roughly 39 percent that tracks cumulative operating burn rather than any productive asset build.
The contraction in total assets is concentrated in cash and near-cash balances, which declined from $135.0 million to $41.1 million over the period. Equity fell alongside it as accumulated deficit deepened, with retained earnings moving from roughly -$1.5 billion to -$1.9 billion. This pattern suggests the balance sheet is being consumed by clinical spend, and investors should monitor whether the trajectory stabilizes or continues to erode toward a point that forces external financing.
Cash Cushion Thin Against Quarterly Burn
According to recent SEC filings, Sana's cash and equivalents of $41.1 million in 2026Q3 compare against operating cash outflows that have frequently exceeded $30 million per quarter, leaving a cushion of only a few quarters.
The current ratio of 1.77 in 2026Q3 appears adequate on paper, but it is supported largely by short-dated balances that will be drawn down by ongoing R&D commitments. The ratio has moved down from above 5 in 2024 as current liabilities have been maintained while current assets shrank. The liquidity position suggests limited tolerance for trial delays or unexpected cost overruns.
Modest Leverage Masks Equity Erosion
As reported in financial statements, Sana's total debt of $53.8 million against equity of $180.4 million yields a debt-to-equity ratio of 0.30, which looks moderate but was 0.63 as recently as 2026Q1.
The reduction in D/E in the latest quarter reflects a rebound in equity rather than meaningful deleveraging, since total debt also declined from $75.3 million. Total liabilities of $195.8 million remain sizable relative to assets, so creditors hold a substantial claim on a shrinking asset base. Investors should treat the current leverage figure with caution, as it may improve or deteriorate sharply depending on how the next financing is structured.
Asset Base Dominated by Goodwill and Intangibles
Based on Sana's reported figures, goodwill of $140.6 million, unchanged across all ten quarters, represents roughly 37 percent of 2026Q3 total assets, while net PP&E has fallen from $135.3 million to $43.4 million.
The flat goodwill balance across the period suggests it has not been tested for impairment in a way that reflects the decline in market value, which warrants further investigation given the persistent losses. The sharp fall in net PP&E points to either asset write-downs or disposals consistent with the pipeline refocusing noted in recent commentary, rather than a deliberate capital-light shift. Tangible asset backing for the equity is therefore weaker than headline total assets imply.
Goodwill Could Overstate Balance Sheet Strength
Based on reported figures, goodwill of $140.6 million exceeds Sana's total equity of $180.4 million less cash, implying that a meaningful portion of book equity could be eliminated by an impairment charge.
Because goodwill has remained static at $140.6 million through periods of severe share price and cash pressure, the headline equity figure may be less durable than it appears. An impairment would reduce equity without any change to cash burn, potentially tightening covenant or financing terms if any are in place. Investors should monitor future filings for impairment testing disclosures before treating book equity as a reliable measure of loss-absorbing capacity.